Compare ACADIA Pharmaceuticals Inc. (ACAD) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs 22nd Century Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while 22nd Century Group Inc trades at $4.3 (market cap $1.48M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 3033.8× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| ACAD | XXII | |
|---|---|---|
Market Cap | $4.49B | $1.48M |
Sector | Health | Technology |
52-Week High | $28.06 | $2.04K |
52-Week Low | $20.06 | $3.90 |
Enterprise Value | $3.69B | -$6.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
XXII trades at $4.28, up 6.73% in the last session, amid a bearish technical outlook. The company reported a net loss of $5.05M on $7.05M revenue in 2025, with negative profitability margins. Recent news highlights expansion of its VLN reduced-nicotine cigarettes into California and New York, aiming to capture market share. A 20:1 reverse stock split was executed on June 12, 2026, to adjust the share structure.
The outlook remains speculative with high execution risk; analyst consensus is 75% buy but fundamentals show deep losses. Key risks include sustained negative cash flow, regulatory hurdles for tobacco products, and reliance on financing. Upside depends on successful commercialization of VLN products and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
